What is the efficacy of gene therapy for hemophilia A?

Updated: Jun 05, 2020
  • Author: Douglass A Drelich, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

Preclinical studies in mice and dogs with hemophilia have resulted in long-term correction of the bleeding disorders and, in some cases, a permanent cure. Preliminary results in human trials of gene therapy for hemophilia B have yielded encouraging results.  Due at least in part to the size of the FVIII gene, development of gene therapy for hemophilia A has proven to be more problematic.ref65} Implantation of liver-derived stem cells that have been expanded in vitro is under consideration, as these could theoretically induce a steady-state production of quantities of factor sufficient to prevent spontaneous bleeding. [66]

In December 2017, Rangarajan et al reported sustained rises in FVIII levels and declines in bleeding rates in patients with severe hemophilia A who received gene therapy with a single intravenous dose of valoctocogene roxaparvovec, a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain–deleted human FVIII. In the seven participants who received a high dose of of valoctocogene roxaparvovec, FVIII activity levels remained in the normal range 1.5 years after gene transfer, and their annualized bleeding rate dropped from 16.5 to 0. All participants were able to completely discontinue prophylactic FVIII infusions, and none developed FVIII inhibitors. [67, 68]   Additional gene therapy products are in clinical trials and this approach may achieve FDA approval in the relatively near term.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!